CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know

Core Viewpoint - Can-Fite Biopharma Ltd (CANF) has received a Zacks Rank 1 (Strong Buy) upgrade due to a positive trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Can-Fite Biopharma indicates an expected earnings per share (EPS) of -$1.25 for the fiscal year ending December 2024, reflecting a 30.2% change from the previous year's reported number [9]. - Over the past three months, the Zacks Consensus Estimate for Can-Fite Biopharma has increased by 95.5%, indicating a strong upward revision trend [9]. Zacks Rating System - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for predicting near-term stock price movements [2][3]. - The system classifies stocks into five groups, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Can-Fite Biopharma's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11].